AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.
|Articles|December 1, 2016
- Applied Clinical Trials-12-01-2016
- Volume 25
- Issue 12
Applied Clinical Trials, December 2016/January 2017 Issue (PDF)
Click the title above to open the Applied Clinical Trials December 2016/January 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Using Public and Private Data for Clinical Operationsalmost 10 years ago
Biomedical R&D Faces New Regulatory Policies and Prioritiesalmost 10 years ago
ICH Approves GCP Guideline Amendmentalmost 10 years ago
How Important is Big Data?almost 10 years ago
Europe’s Drug Regulators Eye a Post-Brexit Prizealmost 10 years ago
FDA Binding Guidance: A Pivotal Milestone for CDISC Standardsalmost 10 years ago
IRB-Investigative Site Relationship Makeoveralmost 10 years ago
New Benchmarks for Trial Initiation Activitiesalmost 10 years ago
Exploring the Role of the Regional Coordinatoralmost 10 years ago
The Role of Big Data in Clinical TrialsAdvertisement
Related to this article
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
2
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
The Test Is the Ticket: Building Smarter Pathways to Clinical Trial Participation
5